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Abstract
Background: It is believed that phosphocitrate (PC) exerts its disease-modifying effects on osteoarthritis (OA) by
inhibiting the formation of crystals. However, recent findings suggest that PC exerts its disease-modifying effect, at least
in part, through a crystal-independent action. This study sought to examine the disease-modifying effects of PC and its
analogue PC-β-ethyl ester (PC-E) on partial meniscectomy-induced OA and the structure-activity relationship.
Methods: Calcification- and proliferation-inhibitory activities were examined in OA fibroblast-like synoviocytes (FLSs)
culture. Disease-modifying effects were examined using Hartley guinea pigs undergoing partial meniscectomy.
Cartilage degeneration was examined with Indian ink, safranin-O, and picrosirius red. Levels of matrix
metalloproteinase-13 (MMP-13), ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5), chemokine
(C-C motif) ligand 5 (CCL5), and cyclooxygenase-2 (Cox-2) were examined with immunostaining. The effects of PC-E
and PC on gene expressions in OA FLSs were examined with microarray. Results are expressed as mean ± standard
deviation and analyzed using Student’s t test or Wilcoxon rank sum test.
Results: PC-E was slightly less powerful than PC as a calcification inhibitor but as powerful as PC in the inhibition
of OA FLSs proliferation. PC significantly inhibited cartilage degeneration in the partial meniscectomied right knee.
PC-E was less powerful than PC as a disease-modifying drug, especially in the inhibition of cartilage degeneration
in the non-operated left knee. PC significantly reduced the levels of ADAMTS5, MMP-13 and CCL5, whereas PC-E
reduced the levels of ADAMTS5 and CCL5. Microarray analyses revealed that PC-E failed to downregulate the
expression of many PC-downregulated genes classified in angiogenesis and inflammatory response.
Conclusions: PC is a disease-modifying drug for posttraumatic OA therapy. PC exerts its disease-modifying effect
through two independent actions: inhibiting pathological calcification and modulating the expression of many genes
implicated in OA. The β-carboxyl group of PC plays an important role in the inhibition of cartilage degeneration, little
role in the inhibition of FLSs proliferation, and a moderate role in the inhibition of FLSs-mediated calcification.
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Background
Osteoarthritis (OA) is a heterogeneous and multifactorial
degenerative joint disease characterized by gradual loss of
articular cartilage, formation of osteophytes, and synovial
inflammation. Current non-surgical treatments for OA,
such as non-steroid anti-inflammatory drugs and steroid
injections, only relieves pain, inflammation, and effusion.
There is a need for the development of disease-modifying
drugs that can not only relieve pain and inflammation, but
also inhibit cartilage degeneration. The lack of progress in
the development of disease-modifying drugs is largely due
to our limited understanding of the pathogenesis of OA
and insufficient knowledge regarding the molecular tar-
gets for therapeutic intervention.
The biochemical events involved in OA are poorly
understood. Many extracellular matrix degrading en-
zymes and inflammatory cytokines, including matrix
metollproteinase-13 (MMP-13), ADAM metallopepti-
dase with thrombospondin type 1 motif 5 (ADAMTS5),
interleukin-1 (IL-1), and cyclooxygenase-2 (Cox-2) have
been implicated in OA [1–3]. Pathological calcification
has also been implicated. Basic calcium phosphate crys-
tals and calcium pyrophosphate dihydrate crystals are
the two most common articular calcium-containing
crystals. The presence of these crystals within the knee
joints of end-stage OA patients is well recognized [4–9].
Injection of these crystals into the knee joints of dogs and
mice induce a severe inflammatory response [10, 11]. These
crystals also induced cell mitogenesis and stimulated the
production of matrix metalloproteinases (MMPs), nitric
oxide, and inflammatory cytokines [12–15], suggesting that
crystals may play a role in the development or progression
of OA.
Phosphocitrate (PC) is a naturally occurring small
molecule originally identified in rat liver mitochondrial
extract [16]. Since its original identification, PC has been
shown to be a powerful calcification inhibitor [17, 18].
PC prevented soft tissue calcification and didn’t produce
any significant toxic side effect in rats in doses up to
150 μmol/kg/day [19]. In addition, PC inhibited crystal-
induced mitogenesis, expression of MMPs, and cell
death [20–22]. Based on these findings, a hypothesis that
PC is a disease-modifying drug for calcification-induced
OA therapy was postulated [23]. A subsequent study
demonstrated that PC inhibited meniscal calcification,
and that a decrease in meniscal calcification was ac-
companied with reduced cartilage degeneration in
Hartley guinea pigs (calcification-induced OA), but
had no significant effect on cartilage degeneration in
partial meniscectomy-induced OA in rabbit (posttrau-
matic OA or non-calcification induced OA) [24]. The
investigators concluded that PC is a disease-modifying
drug for calcification-induced OA therapy but not for
non-calcification-induced OA. It was believed that PC
exerted its OA disease-modifying activity by inhibiting
the formation of articular calcium crystals and the det-
rimental interaction between these crystals and joint
cells (crystal-dependent action) [23, 24]. Although this
theory was well received at the time, doubt emerged
upon the findings that bisphosphonates, which were
potent calcification inhibitors [25, 26], failed to inhibit
cartilage degeneration in animal models of OA, includ-
ing Hartley guinea pig model of calcification-induced
OA [27, 28].
We recently found that PC downregulated the expres-
sion of many genes classified in cell proliferation, angio-
genesis, and inflammatory response, while upregulating
the expressions of many genes classified in skeletal system
development in the absence of calcium crystals [29–31].
These newer findings suggest that crystal-dependent ac-
tion of PC may not be a sole action underlying the OA
disease-modifying effect of PC. It is likely that PC exerts
its OA disease-modifying activity through two inde-
pendent actions: i) inhibiting the formation of crystals
and crystal-induced expressions of MMPs (a crystal-
dependent action), and ii) modulating the expressions of
genes implicated in OA (a crystal-independent action).
PC-β-ethyl ester (PC-E) is a PC analogue where a β-
carboxyl group is replaced by an ethyl ester group (Fig. 1).
We are interested in PC-E not only because compared to
PC, PC-E has less negative charges, therefore it may be
more easily absorbed in the intestine if administered
through the oral route, but also because novel new PC ana-
logues may be prepared by linking other active group(s) to
this carboxyl group. In this study, we sought to examine
disease-modifying activity of PC and PC-E on posttrau-
matic OA and investigate the structure-activity relationship.
The results of this study may not only provide information
Fig. 1 Molecular structures of PC and PC-E
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valuable for the design and development of new PC ana-
logues as disease-modifying drug for OA therapy, but also
for a better understanding of pathogenesis of OA and the
molecular mechanism underlying the disease-modifying ac-
tivity of PC.
Methods
Dulbecco’s minimum essential medium (DMEM), fetal
bovine serum, stock antibiotic/antimycotic mixture
were obtained from Invitrogen (Carlsbad, CA). 45Cal-
cium was obtained from Perkin-Elmer (Boston, MA).
Antibody specific to MMP-13 (Lifespan Biosciences,
Seattle, WA), ADAMTS5 (Santa Cruz Biotechnology,
Dallas, TX), Cox-2 (Santa Cruz Biotechnology, Dallas,
TX), and CCL-5 (Bioss, Woburn, MA) were obtained
from the commercial sources indicated. Safranin-O,
fast green, picrosirius red, and alcian blue were ob-
tained from Polysciences (Warrington, PA). PC and
PC-E were prepared according to the method de-
scribed [32]. All other chemicals were obtained from
Sigma-Aldrich (St. Louis, MO).
Calcification assay
OA fibroblast-like synoviocytes (FLSs), similar to OA
chondrocytes, play a role in the formation of articular
crystal [9, 33, 34]. To compare the calcification-
inhibitory activity of PC and PC-E, we performed an
ATP-induced calcification assay using telomerase im-
mortalized human OA fibroblast-like synoviocytes
(FLSs), hTERT-OA 13A FLSs [9]. Briefly, hTERT-OA
13A FLSs were plated in a 24 well cluster plate at 95 %
confluence. On the second day, DMEM with 10 % serum
was changed to DMEM containing 0.5 % serum. On the
third day, after cells became quiescent, DMEM contain-
ing 1 mM ATP and trace-labeled with 1 μCi/ml 45cal-
cium was added. Immediately, increasing amounts of
PC, PC-E, or citrate were added into the wells. Forty-
eight hours later, cells were washed with cold Hank’s
balanced salt solution five times and lysed with 0.1 N
NaOH. Radioactivity of lysate in each well was quanti-
fied using liquid scintigraphy. Calcification-inhibitory ac-
tivity of disodium ethane-1-hydroxy-1, 1-diphosphonate
(EHDP) was also examined. Results were presented as
the mean ± SD of five independent experiments.
Proliferation assay
Proliferation-inhibitory activities of PC-E and PC were
examined as described [29]. Briefly, hTERT-OA 13A
FLSs (4×104) were plated in six well cluster plates. On
the second day, DMEM containing 10 % serum and PC-
E (0.5 mM) or PC (0.5 mM) was added into the top
three wells. DMEM containing 10 % serum without PC-
E or PC was added into the bottom three wells as a con-
trol. DMEM was changed every three days until the cells
in the bottom wells reached 85 % confluence (cultured
for about 12 to 14 days). All cells were then harvested
and the cell number in each well was counted. Results
were presented as the mean ± SD of three independent
experiments.
Experimental animals
This study was performed according to the guidelines
set forth by the Institutional Animal Care & Use Com-
mittee of Carolinas Medical Center, which approved the
animal protocol. Male Hartley guinea pigs at three weeks
of age were obtained from Charles River Laboratories (Wil-
mington, MA) and individually housed in 29 × 21 × 10 inch
solid bottom cages. Guinea Pig Chow (No. 5025; Ralston
Purina, Richmond, Indiana) and water were available ad
libitum. The first group of guinea pigs (n = 5) received in-
traperitoneal injection of PC (40 mg/kg) twice per week,
second group (n = 5) received PC-E (40 mg/kg) and the last
group (n = 5) received physiological saline. Two months
later, partial medial meniscectomy was performed on the
right knee of all guinea pigs to induce posttraumatic OA. A
week after the surgery, injection of PC, PC-E, or saline was
resumed. Five months later, these guinea pigs were eutha-
nized by the administration of Euthasol (Virbac Animal
Health, Ft. Worth, Texas). Hind limbs were collected, fixed
in 10 % formalin, and transferred to 70 % ethanol until use.
Structural changes in the articular cartilage of Hartley
guinea pigs were not observed until three months of age
[35], therefore pretreatment of the young guinea pigs with
PC or PC-E for two months before partial meniscectomy
surgery will not result in detectable structural changes in
the articular cartilage.
Radiographic, microscopic, and histological examinations
Radiographs of knee joints were obtained with a digital
radiography system (piXaray 100, Bioptics Inc., Tucson,
AZ). After dissection of the knee joints, radiographs of
medial meniscus were obtained. All tibia plateaus were
first stained with Indian ink as described [36]. The tibia
plateaus were then decalcified in Cal-Ex II solution
(Fisher Scientific, Fairlawn, NJ) and cut coronally in the
center to produce two equal portions. The posterior por-
tion was embedded in paraffin and sectioned with a
Leica RM2025 microtome (Nussloch, Germany) to ob-
tain 4 μm sections. Three non-consecutive sets of sec-
tions (three consecutive sections in each set) obtained at
400 μm intervals were stained with safranin-O and
counter stained with fast green. These sections (nine
sections for each cartilage specimen) were graded ac-
cording to standard Mankin criteria with minor modifi-
cations [37]. Two sections in each cartilage specimens
were also stained with picrosirius red and counter
stained with alcian blue.
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Cartilage thickness
Central portion of safranin-stained sections (the most de-
generative area) was photographed and the area of cartil-
age (same length for each section) was measured using
the measuring tool in Adobe acrobat software (San Jose,
CA). Briefly, the image file was opened with Adobe acro-
bat and the cartilage was traced continuously with the
“pen” in the measuring tool along the irregular surface of
the articular cartilage (numerous very short straight lines
were connected together to form an irregular line) and the
border between cartilage and subchondral bone. After tra-
cing the cartilage was finished, the area was automatically
calculated. Cartilage thickness is obtained by dividing the
area with the length of the cartilage measured.
Immunohistochemistry
Two sections in each tibia plateau were deparaffinized
with xylene and rehydrated with graded ethanol. En-
dogenous peroxidase activity was blocked by incubation
with deionized water containing 3 % H2O2 for five mi-
nutes. Non-specific binding was blocked by incubation
with 100 μl of 10 % normal horse serum diluted in base
solution (4 % BSA and 5 % non-fat dry milk in PBS) for
20 min. These sections were incubated with primary
antibodies (1:100 dilution) for one hour, followed with
secondary reagent for 30 min (Immpress reagent kit,
Vector, Inc., Burlingame, CA). Negative control was per-
formed using mouse IgG. Slides were rinsed in phos-
phate buffered saline three times and visualized with 3,
3′-diaminobenzidin. Slides were counterstained with light
green, dehydrated and mounted with resinous mounting
media. These slides were graded on a scale of 0–4, where
0 = very weak staining; 1 = weak staining; 2 =moderate
staining; 3 = strong staining; 4 = very strong staining as
described [38].
Microarray
Briefly, hTERT-OA 13A FLSs [9] were plated in two
100 mm plates at 90 % confluence. On the second day,
medium was changed to medium containing 1 % serum.
On the third day, medium containing 1 % serum and
PC-E (0.6 mM) was added to a plate, and medium con-
taining 1 % serum but without PC-E was added to the
other plate. Twenty-four hour later, total RNA was ex-
tracted using Trizol reagent (Invitrogen, Carlsbad, CA)
and purified using Oligotex kit (Qiagen, Valencia, CA).
These RNA samples were used for microarray as de-
scribed [29]. Microarray analysis of PC on gene expres-
sions has been performed previously [29].
Statistical analyses
Results of calcification assay, proliferation assay, and car-
tilage thickness measurements (variables measured on
continuous interval) are presented as the mean ± SD.
The differences between the results in 2 groups were an-
alyzed using Student’s t Test. Scores of histological stain-
ing and immunostaining (variables presented as ordinal
data) were presented as the mean ± SD. The differences
between the scores in two groups were analyzed using
Wilcoxon rank sum test. Statistical analysis was per-
formed using the statistical analysis tool in the Sigma Plot
software, version 12 (Systat Software, Inc., San Jose, CA).
Results
Calcification- and proliferation-inhibitory activities
PC, PC-E, and EHDP, but not citrate, inhibited ATP-
induced calcium deposition in a dose dependent manner
(Fig. 2a). PC is the most potent calcification inhibitor, with
PC-E being 19 % and EHDP being 13 % less powerful than
PC in the inhibition of OA FLSs-mediated calcium depos-
ition at the concentration of 0.25 mM (p < 0.01). PC-E,
similar to PC [29], also inhibited the proliferation of hu-
man OA FLSs (Fig. 2b). There were about 66 % and 64 %
fewer human OA FLSs in the PC and PC-E treated wells,
respectively, compared to controls (p < 0.01). PC and
PC-E had no effect on cell viability up to the concentra-
tion of 10 mM whereas EHDP caused cell death when
its concentration was higher than 1.5 mM (not shown).
Fig. 2 Calcification- and proliferation-inhibitory activities. a PC, PC-E, and EHDP inhibit OA FLSs-mediated calcification. CPM (count per minute) in
control, PC-E, PC and EHDP treated cells are 22,784 (±2,156), 6,452 (±1,095), 2,466 (±352), and 5,124 (±1114), respectively, at the concentration of
0.25 mM. b PC and PC-E inhibit OA FLSs proliferation. Cell numbers in control and PC treated wells are 845,236 (±89,521) and 285,706 (±34,132).
Cell numbers in control and PC-E treated wells are 924,484 (±98,718) and 331,096 (±48,694). *= p < 0.01, versus control
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Radiographic examinations
Representative radiographs of the knee joints and medial
menisci were provided in Fig. 3. As expected, calcified
medial meniscus was observed in the non-operated left
knee, but not in the meniscectomied right knee (Fig. 3a).
Meniscal calcification predominantly occurred in the an-
terior horn of the medial meniscus (Fig. 3b). The se-
verely calcified anterior horn of the medial meniscus
was absent in the meniscectomied right knee. As shown
in Fig. 3a, meniscus in the non-operated left knee of PC
and PC-E treated guinea pigs were slightly less calcified
compared to untreated guinea pigs, indicating that PC
and PC-E reduced meniscal calcification. However,
meniscal calcification in PC and PC-E treated guinea
pigs appeared similar. No signs of cartilage calcification
were observed.
Microscopic examinations
Indian ink staining was used to examine the tibia plat-
eaus of all guinea pigs. Representative Indian ink stained
tibia plateaus are provided in Fig. 4. As shown, cartilage
damage, visualized with the help of Indian ink, spanned
a larger area in the medial tibia plateaus of the menis-
cectomied right knee than the cartilage damage in the
medial tibia plateaus of the non-operated left knee
(Fig. 4a). In the non-operated left knee, cartilage damage
was confined in the central area of the medial tibia plat-
eau (Green arrow) whereas in the meniscectomied right
knee, cartilage damage was not only present in the central
area (Green arrow) but also present in the peripheral area
that was originally covered with meniscus (Red arrow).
These results demonstrated that meniscal injury and joint
instability resulted in increased cartilage degeneration, es-
pecially cartilage degeneration in the peripheral area,
which was not observed in the non-operated left knee. As
shown in Fig. 4b and c, there was less cartilage damage in
the medial tibia plateau of the meniscectomied right knee,
especially in the peripheral area, in PC and PC-E treated
guinea pigs compared to untreated controls, indicating
that PC and PC-E inhibited cartilage degeneration in-
duced by meniscal injury and joint instability. There was
also less cartilage damage in the medial tibia plateau of
the non-operated left knee in PC and PC-E treated guinea
pigs compared to untreated controls.
Histological examinations
Representative three non-consecutive safranin-O stained
sections from the meniscectomied right knee in untreated
and PC treated guinea pigs were provided in Fig. 5. Con-
sistent with Indian ink staining, safranin-O staining re-
vealed that severe cartilage damage occurred in both the
central and peripheral areas of medial tibia plateau in
Fig. 3 Radiographs of knees and medial menisci. a Representative radiographs of meniscectomied right knee and non-operated left knee of untreated,
PC-treated, and PC-E treated guinea pigs. Calcified medial menisci are indicated by arrows. b Radiographs of the meniscectomied right knee medial
meniscus and the non-operated left knee medial meniscus of an untreated guinea pig. Severely calcified anterior horn of the medial meniscus (arrow)
is present in the left knee, but not in the right knee
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Fig. 4 Representative images of Indian ink staining. a Indian ink-stained tibia plateaus of the meniscectomied right knee and the non-operated
left knee of an untreated guinea pig. b Indian ink-stained tibia plateaus of the meniscectomied right knee and the non-operated left knee of a
PC-treated guinea pig. c Indian ink-stained tibia plateaus of the meniscectomied right knee and the non-operated left knee of a PC-E-treated
guinea pig. Green arrow - central area of medial tibia plateau. Red arrow - peripheral area of medial tibia plateau
Fig. 5 Safranin-O stained sections of medial tibia plateaus of meniscectomied right knee. a A section in the central area of medial tibia plateau of
an untreated and a PC treated guinea pig. b Second section, 400 μm away from first section. c Third section, 800 μm away from first section.
Green arrows - central area of medial tibia plateau. Red arrows - peripheral area
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untreated guinea pigs. Cartilage damage and proteoglycan
loss, in many cases, extended into deep and calcified
zones. Cartilage damage and proteoglycan loss were sig-
nificantly reduced in PC treated guinea pigs. In the central
area of medial tibia plateaus, mild to moderate cartilage
damage and proteoglycan loss were observed, whereas in
the peripheral area, only mild cartilage damage and pro-
teoglycan loss were observed. Consistent with Indian ink
staining, cartilage damage and proteoglycan loss were also
reduced in PC-E treated guinea pigs (photos not shown).
In addition, cartilage in untreated guinea pigs appeared
thinner than the cartilage in PC treated guinea pigs (Fig. 5).
We measured the cartilage thickness of all guinea pigs as
described. As shown in Fig. 6a, cartilage in PC treated
guinea pigs was 31 % thicker than the cartilage in un-
treated guinea pigs (p = 0.01). Similarly, PC-E also inhib-
ited cartilage thinning. Cartilage in PC-E treated guinea
pigs was 18 % thicker than the cartilage in untreated
guinea pigs (p = 0.02).
These safranin-O stained sections (nine sections for
each tibia plateau specimen) were graded. As shown in
Fig. 6b, PC and PC-E significantly reduced the histologic
score of medial tibia plateau (black bars), resulting in a
46 and 30 % reduction in the histological scores, re-
spectively (p < 0.05). For comparison, safranin-O stained
sections in the non-operated left knee medial tibia plat-
eau were graded. The histological score of the medial
tibia plateau in the non-operated left knee was much
lower than the histological score of the medial tibia plat-
eau in the meniscectomied right knee (p < 0.01), con-
firming that meniscal injury and joint instability resulted
in significantly increased cartilage damage. PC and PC-E
reduced the histologic score of the medial tibia plateau
in the non-operated left knee (grey bars), resulting in a
54 and 28 % reduction in the histological scores, re-
spectively (p < 0.05).
Due to severe cartilage damage being observed in the
peripheral area of the medial tibia plateau in the menis-
cectomied right knee but not in the non-operated left
knee, we decided to grade the peripheral area specific-
ally. As shown in Fig. 6c, meniscal injury and joint in-
stability in the meniscectomied right knee resulted in
severe cartilage degeneration in the peripheral area com-
pared to the non-operated left knee. Cartilage damage in
the peripheral area of the medial tibia plateau in the
meniscectomied right knee was significantly reduced in
PC and PC-E treated guinea pigs, indicating again that
PC and its analogue inhibits injury and joint instability-
induced cartilage degeneration.
Two sections in each tibia plateau were also stained with
picrosirius red and counter-stained with alcian blue. Rep-
resentative images of picrosirius red stained sections are
provided in Fig. 7. As shown, severe cartilage damage was
observed in the untreated guinea pigs and in many cases,
Fig. 6 Cartilage thickness and histological scores of medial tibia
plateaus. a Normalized cartilage thickness in untreated, PC-treated, and
PC-E treated guinea pigs are 1 (±0.11), 1.31 (±0.13), and 1.18 (±0.10).
* p < 0.01, versus controls. b Histological scores of medial tibia plateau
in the meniscectomied right knee in untreated, PC, and PC-E treated
guinea pigs are 11.95 (±1.05), 6.43 (±0.93), and 8.24 (±0.1.37). Histological
scores of medial tibia plateau in the non-operated left knee in untreated,
PC, and PC-E treated guinea pigs are 8.11 (±1.39), 3.72 (±0.91), and 5.74
(±0.12). * p< 0.05, versus controls. c Histological scores of the peripheral
area of medial tibia plateau in the non-operated left knee and the
meniscectomied right knee of untreated guinea pigs are 2.92 (±0.45)
and 8.67 (±0.74). Histological scores of the peripheral area of medial tibia
plateau in the meniscectomied right knee of PC and PC-E treated guinea
pigs are 4.59 (±0.81) and 6.42 (±0.0.86). * p< 0.05, versus controls
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cartilage lesions extended into the middle, deep, and calci-
fied zones. In contrast, cartilage damage was much less
prominent in PC treated guinea pigs. Surprisingly, unlike
the severe loss of safranin-O staining, there was no severe
loss of picrosirius red staining in untreated guinea pigs
compared to PC treated guinea pigs. These findings indi-
cate that OA cartilage in the untreated Hartley guinea pigs
was characterized by breakdown of collagen fibers, not by
collagen loss. Interestingly, alcian blue staining was ob-
served in some chondrocytes residing in the middle zone
of articular cartilage in the untreated guinea pig, which
was not observed in the cartilage of PC-treated guinea
pigs. One explanation for this finding is that some chon-
drocytes in OA cartilage synthesize more proteoglycans in
response to matrix degeneration. Consistent with this ex-
planation, the intensity of safranin-O staining in the nu-
cleus and cytoplasm of some chondrocytes in the untreated
guinea pigs appeared much higher than the intensity of
safranin-O staining in the nucleus and cytoplasm of most
chondrocytes in the PC-treated guinea pigs (Fig. 5). Severe
loss of safranin-O staining in the articular cartilage of un-
treated guinea pigs mainly occurred in the extracellular
matrix space (Fig. 5).
Immunohistochemistry
Representative images of immunostaining are provided in
Fig. 8a. In untreated guinea pigs, high levels of ADAMTS-5
protein was present in superficial, middle, and deep zones,
whereas high level of MMP-13 protein was present in the
middle and deep zones. The level of ADAMTS5 protein
was reduced in PC and PC-E treated guinea pigs. The level
of MMP-13 protein was also reduced, especially in the mid-
dle zone in PC treated guinea pigs. However, the level of
MMP-13 protein appeared only slightly reduced in PC-E
treated guinea pigs. In untreated guinea pigs, CCL-5 pro-
tein was present in superficial, middle, and deep zones,
whereas Cox-2 protein was present in superficial and mid-
dle zones. It was clear that the level of CCL-5 protein was
reduced in PC and PC-E treated guinea pigs. However, the
level of Cox-2 protein appeared only slightly reduced in PC
and PC-E treated guinea pigs compared to the untreated
controls.
The scores of these immunostainings are provided in
Fig. 9. As shown, PC and PC-E treatments resulted in
42 % and 38 % reductions in the immunostaining score
of ADAMTS5, respectively (p < 0.05). PC treatment also
resulted in 44 % reduction in the immunostaining score
of MMP-13 (p < 0.05). Although PC-E treatment re-
sulted in reduction in the immunostaining score of
MMP-13 (16 %), the difference did not reach statistical
significance. PC and PC-E treatment resulted in 35 %
and 40 % reductions in the immunostaining score of
CCL-5, respectively (p < 0.05). Although PC and PC-E
treatments resulted in reductions in the immunostaining
score of Cox-2 (about 10-14 % reductions), the differ-
ences did not reach statistical significance.
The effect of PC-E on gene expressions
We have shown that PC downregulated the expression of
numerous genes classified in cell proliferation, angiogenesis,
Fig. 7 Picrosirius red stained sections. Left: section at the central area of the medial tibia plateau from two untreated guinea pigs. Right: section
at the central area of the medial tibia plateau from two PC treated guinea pigs
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and inflammatory response while upregulating the expres-
sion of many genes classified in skeletal system develop-
ment in the absence of calcium crystals [29]. To examine
the molecular mechanisms underlying the decreased
disease-modifying activity of PC-E, we compared the effect
of PC-E on gene expressions with the effect of PC on gene
expressions [29]. As shown in Table 1, PC-E downregulated
almost all of the PC-downregulated genes classified in cell
proliferation, suggesting that PC-E may inhibit cell prolifer-
ation as effectively as PC. However, PC-E had little effect
on the expression of most of the PC downregulated
genes classified in angiogenesis and inflammatory re-
sponse, including prostaglandin-endoperoxide synthase
2 (PTGS2/Cox-2). PC-E also had little effect on the
Fig. 8 Immunostaining. a Immunostaining of ADAMTS5, MMP-13, CCL-5, and Cox-2. No staining was noted in negative control. b Enlarged images of
immunostaining of ADAMTS5, MMP-13, CCL-5, and Cox-2 in untreated guinea pigs. ADAMTS staining was mainly found in the pericellular area and
extracellular matrix, whereas MMP-13 staining was found in the nucleus, cytoplasm, pericellular area, and extracellular matrix. CCL-5 staining was found
in the nucleus, cytoplasm, and pericellular area. Cox-2 staining was mainly found in the nucleus and cytoplasm
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expressions of most of the PC upregulated genes classi-
fied in muscle tissue and skeletal system development
(Table 2).
Discussion
PC, PC-E, and EHDP are powerful calcification inhibi-
tors, suggesting that the phosphate group within these
molecules play a key role in their calcification-inhibitory
activity. These findings cast some doubt about the role
of the calcification-inhibitory activity of these molecules
in their OA disease-modifying activity because bispho-
sphonates displayed little disease-modifying effect on the
animal model of OA [27, 28]. PC, consistent with previ-
ous findings [18, 26], is more powerful than EHDP as a
calcification inhibitor, suggesting that the three carboxyl
groups also play a key role in the calcification-inhibitory
activity of PC. However, replacement of the β-carboxyl
group with a β-ester group only resulted in a moderate
19 % reduction in the calcification-inhibitory activity of
PC, indicating that three carboxyl groups are required
for the strong calcification-inhibitory activity and that a
single carboxyl group only plays a moderate role in the
calcification-inhibitory activity of PC.
PC-E, similar to PC, inhibited the proliferation of OA
FLSs. Consistent with this finding, PC-E downregulated
the expressions of almost all of the PC-downregulated
genes classified in cell proliferation as effectively as PC
(Table 1). These findings indicate that the β-carboxyl
group plays little role in the proliferation-inhibitory ac-
tivity of PC and that the phosphate group within these
molecules plays a key role in the proliferation-inhibitory
activity [29]. Because PC-E is much less powerful than
PC as an OA disease-modifying drug, it suggests that
the proliferation-inhibitory activity of PC plays little role
in its OA disease-modifying activity and that those PC
downregulated genes classified in cell proliferation are
unlikely key OA disease candidate genes.
Medial meniscal calcification is absent in the menis-
cectomied right knee and severe articular cartilage calci-
fication is not observed in the Hartley guinea pigs [24];
therefore, OA in the meniscectomied right knee was
mainly induced by meniscal injury and joint instability,
and had less to do with pathological calcification. In this
model of posttraumatic OA, PC significantly reduced
cartilage damage and proteoglycan loss, demonstrating
that PC is a disease-modifying drug for posttraumatic
OA therapy. We should point out that our finding and
conclusion contradict with a previous study. Cheung et
al. found that PC had no significant effect on cartilage
degeneration in partial meniscectomied rabbits, and
concluded that PC is potentially a disease-modifying
drug for calcification-induced OA, but not for non-
calcification-induced OA [24]. One possible explanation
for these contradicting findings is that different doses of
PC were used in the two studies. A single weekly injec-
tion (40 mg/kg) was used in the previous study whereas
two weekly injections of PC (40 mg/kg) were used in this
study. It is worth noting that PC treatment did reduce
the histological score of the medial tibia in the rabbit
(from 9.8 ± 1.7 to 8.1 ± 2.2) [24]. If higher doses or more
injections of PC per week was used, statistically signifi-
cant difference might have been observed.
The molecular mechanisms underlying the disease-
modifying effect of PC remain poorly understood. If PC
exerted its disease-modifying effect solely by inhibiting
the formation of articular crystals, PC should have dis-
played little disease-modifying effect on posttraumatic
OA. Moreover, PC-E should have displayed only moder-
ately decreased disease-modifying effect on posttrau-
matic OA compared to PC because PC-E is still a
powerful calcification inhibitor. However, we found that
PC significantly inhibited cartilage degeneration and that
PC-E was 46 % less powerful than PC in the inhibition
of cartilage degeneration in the meniscectomied right
Fig. 9 Scores of immunostaining. Scores for ADAMTS5 immunostaining in untreated, PC, and PC-E treated guinea pigs are 2.40 (±0.61), 1.40 (±0.49),
and 1.50 (±0.45); Scores for MMP-13 immunostaining are 3.20 (±0.71), 1.80 (±0.64), and 2.70 (±0.55); Scores for CCL-5 immunostaining are 2.00 (±0.55),
1.30 (±0.35), and 1.20 (±0.33); Scores for Cox-2 immunostaining are 1.40 (±0.40), 1.20 (±0.55), and 1.20 (±0.49). *p < 0.05, versus controls
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Table 1 Differentially expressed genes in PC-treated and PC-E-treated cells compared with untreated cells






BLM NM_000057 −3.64 −1.78 Bloom syndrome
CCNE2 AF112857 −3.74 0.00 Cyclin E2
CCNE1 AI671049 −2.30 0.00 Cyclin E1
CDC25A AY137580 −3.63 0.00 Cell division cycle 25 homolog A (S. pombe)
CDC25C NM_001790 −2.31 0.00 Cell division cycle 25 homolog C (S. pombe)
CDC2 AA749427 −3.13 −3.42 Cell division cycle 2, G1 to S and G2 to M
CDC6 NM_001254 −2.36 −9.19 Cell division cycle 6 homolog (S. cerevisiae)
CDC7 NM_003503 −2.12 −4.42 Cell division cycle 7 homolog (S. cerevisiae)
CDCA3 NM_031299 −1.83 −2.61 Cell division cycle associated 3
CDCA5 BE614410 −2.41 −3.37 Cell division cycle associated 5
CDCA7 AY029179 −2.36 −4.60 Cell division cycle associated 7
CDCA8 BC001651 −2.11 −2.12 Cell division cycle associated 8
CDK2 AB012305 −2.74 −3.36 Cyclin-dependent kinase 2
NCAPH D38553 −2.64 −2.21 Non-SMC condensin I complex, subunit H
HELLS NM_018063 −2.49 −4.77 Helicase, lymphoid-specific
AURKB AB011446 −2.43 0.00 Aurora kinase B
KIF23 AW192521 −2.41 −3.83 Kinesin family member 23
CLASP2 BC029035 −2.40 0.00 Cytoplasmic linker associated protein 2
NUF2 AF326731 −2.35 −4.04 NUF2, NDC80 kinetochore complex component,
homolog
DSN1 NM_024918 −2.35 −3.09 DSN1, MIND kinetochore complex component,
homolog
SPC24 AI469788 −2.32 0.00 SPC24, NDC80 kinetochore complex component,
homolog
SPC25 AF225416 −2.10 −3.40 SPC25, NDC80 kinetochore complex component,
homolog
HMGA2 AI990940 −2.30 −3.41 High mobility group AT-hook 2
LIG1 NM_000234 −2.25 −2.20 Ligase I, DNA, ATP-dependent
KIFC1 BC000712 −2.21 −2.08 Kinesin family member C1
BRCA2 X95152 −2.18 0.00 Breast cancer 2, early onset
ERCC6L NM_017669 −2.17 −2.29 Exc repair cross-comp repair deficiency, comp group
6-like
SPAG5 NM_006461 −2.16 −2.61 Sperm associated antigen 5
NEK2 Z25425 −2.14 −2.20 NIMA (never in mitosis gene a)-related kinase 2
NCAPG NM_022346 −2.12 −4.06 Non-SMC condensin I complex, subunit G
ZWINT NM_007057 −2.01 −3.93 ZW10 interactor antisense
PARD3B AF428251 3.24 1.68 Par-3 partitioning defective 3 homolog B (C. elegans)
11-Sep AI333326 2.28 0.00 Septin 11
Angiogenesis
NRP1 AF280547 −2.69 0.00 Neuropilin 1
TEK BF594294 −2.58 −1.73 TEK tyrosine kinase, endothelial
ELK3 NM_005230 −2.42 0.00 ELK3, ETS-domain protein (SRF accessory protein 2)
EREG NM_001432 −1.90 0.00 Epiregulin
PML AW291023 −1.89 0.00 Promyelocytic leukemia
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knee. These findings indicate that crystal-dependent ac-
tion is unlikely the sole action underlying the disease-
modifying effect of PC or PC-E. PC and PC-E likely
exert their disease-modifying activity through both a
crystal-dependent action and a crystal-independent ac-
tion. Consistent with this mechanism, PC-E had no ef-
fect on the expressions of PC downregulated genes
classified in angiogenesis and inflammatory response
Table 1 Differentially expressed genes in PC-treated and PC-E-treated cells compared with untreated cells (Continued)
COL15A1 NM_001855 −1.80 0.00 Collagen, type XV, alpha 1
NRP2 AI819729 −1.75 0.00 Neuropilin 2
SPHK1 NM_021972 −1.72 0.00 Sphingosine kinase 1
FOXC2 NM_005251 −1.68 0.00 Forkhead box C2 (MFH-1, mesenchyme forkhead 1)
SCG2 NM_003469 −1.66 2.54 Secretogranin II (chromogranin C)
EDNRA NM_001957 −1.56 0.00 Endothelin receptor type A
TGFBR2 NM_003242 −1.51 −1.97 Transforming growth factor, beta receptor II (70/
80 kDa)
ROBO4 AA156022 −1.51 0.00 Roundabout homolog 4, magic roundabout
(Drosophila)
JAG1 AI457817 2.42 1.76 Jagged 1 (Alagille syndrome)
NOTCH4 AI341271 1.75 0.00 Notch homolog 4 (Drosophila)
RUNX1 D89788 1.73 0.00 Runt-related transcription factor 1
EPAS1 NM_001430 1.67 0.00 Endothelial PAS domain protein 1
Inflammatory
response
PTGS2 AY151286 −6.09 0.00 Prostaglandin-endoperoxide synthase 2
SERPINA1 AF119873 −2.15 0.00 Serpin peptidase inhibitor, clade A
GPR68 AI805006 −2.15 −2.44 G protein-coupled receptor 68
BMPR1B AA935461 −2.12 0.00 Bone morphogenetic protein receptor, type IB
EVI1 BE466525 −2.00 −1.69 Ecotropic viral integration site 1
FOS BC004490 −1.92 1.51 V-fos FBJ murine osteosarcoma viral oncogene
homolog
IRAK2 AI246590 −1.82 0.00 Interleukin-1 receptor-associated kinase 2
CCL2 S69738 −1.82 0.00 Chemokine (C-C motif) ligand 2
CCR1 NM_001295 −1.60 0.00 Chemokine (C-C motif) receptor 1
CXCL2 M57731 −1.66 0.00 Chemokine (C-X-C motif) ligand 2
SPN BC035510 −1.79 0.00 Sialophorin (leukosialin, CD43)
TLR4 AF177765 −1.70 0.00 toll-like receptor 4
SCG2 NM_003469 −1.66 2.54 Secretogranin II (chromogranin C)
FN1 AJ276395 −1.58 −1.52 Fibronectin 1
KLKB1 BE326857 −1.52 0.00 Cytochrome P450, family 4, subfamily V, polypeptide
2
NDST1 NM_001543 2.05 0.00 N-deacetylase/N-sulfotransferase (heparan
glucosaminyl) 1
C3 NM_000064 2.05 0.00 Complement component 3
SERPINA3 NM_001085 1.88 0.00 Serpin peptidase inhibitor, clade A
SBNO2 AC005390 1.78 0.00 strawberry notch homolog 2 (Drosophila)
NFKBIZ BE646573 1.74 0.00 NF-KB inhibitor zeta
MASP1 NM_001879 1.64 0.00 Mannan-binding lectin serine peptidase 1
STAT5B NM_012448 1.59 0.00 Signal transducer and activator of transcription 5B
*Negative number indicates decreased expression (fold) in treated hTERT-OA 13A FLS compared with untreated cells
Positive number indicates elevated expression (fold) in treated hTERT-OA 13A FLS compared with the untreated cells
**Dada was published previously [29]
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Table 2 Differentially expressed genes in PC-treated and PC-E-treated cells compared with untreated cells







IGFBP5 AW157548 8.57 1.55 Insulin-like growth factor binding protein 5
CACNB4 NM_000726 2.73 0.00 Calcium channel, voltage-dependent, beta 4 subunit
TPM1 AI521618 2.43 0.00 Tropomyosin 1 (alpha)
JAG1 U61276 2.02 0.00 Jagged 1 (Alagille syndrome)
MORF4L2 H43976 1.90 0.00 Mortality factor 4 like 2
NRG1 NM_013957 1.88 0.00 Neuregulin 1
SIRT2 BG722779 1.86 0.00 Sirtuin (silent mating type information regulation 2
homolog) 2
NF1 D12625 1.80 0.00 Neurofibromin 1
OBSL1 BF446688 1.78 0.00 Obscurin-like 1
MBNL1 AA732240 1.73 0.00 Muscleblind-like (Drosophila)
TPM1 NM_000366 1.72 0.00 Tropomyosin 1 (alpha)
CAV2 AA150110 1.67 0.00 Caveolin 2
RXRA BE675800 1.66 0.00 Retinoid X receptor, alpha
NR2F2 AL554245 1.63 0.00 Nuclear receptor subfamily 2, group F, member 2
TCF7L2 AV721430 1.61 2.00 Transcription factor 7-like 2 (T-cell specific, HMG-box)
TBX2 U28049 −4.17 0.00 T-box 2
ADRB2 NM_000024 −2.36 0.00 Adrenergic, beta-2-, receptor, surface
SORT1 BE742268 −1.93 0.00 Sortilin 1
GJC1 NM_005497 −1.77 −3.09 Gap junction protein, gamma 1, 45 kDa
CENPF U30872 −1.77 0.00 Centromere protein F, 350/400 ka (mitosin)
BCL2 NM_000657 −1.71 1.55 B-cell CLL/lymphoma 2
TBX3 U69556 −1.71 1.77 T-box 3
SDC1 NM_002997 −1.65 −1.89 Syndecan 1
TBX5 AW269421 −1.54 0.00 T-box 5
RARB NM_015854 −1.51 0.00 Retinoic acid receptor, beta
Skeletal development
ANXA2 D28364 2.17 0.00 Annexin A2
VDR AA772285 2.11 0.00 Vitamin D (1,25- dihydroxyvitamin D3) receptor
GNAS AI693143 1.95 1.60 GNAS complex locus
ACAN NM_001135 1.80 −1.51 Aggrecan
COL1A1 AI743621 1.66 0.00 Collagen, type I, alpha 1
COL1A2 AA628535 1.88 0.00 Collagen, type I, alpha 2
COL11A1 NM_001854 1.50 0.00 Collagen, type XI, alpha 1
COL12A1 AU146651 1.93 1.51 Collagen, type XII, alpha 1
MSX2 D89377 1.85 0.00 Msh homeobox 2
GHR NM_000163 1.76 0.00 Growth hormone receptor
MEF2C AL536517 1.59 0.00 Myocyte enhancer factor 2C
THRA NM_003250 1.57 1.60 Thyroid hormone receptor, alpha
RUNX2 AW469546 1.55 1.89 Runt-related transcription factor 2
CLEC3B NM_003278 1.55 3.26 Exosome component 7
MEF2C N22468 1.55 0.00 Myocyte enhancer factor 2C
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and PC upregulated genes classified in skeletal system de-
velopment; therefore, resulting in decreased OA disease-
modifying activity. Taken together, it suggests that the
gene expression-modulatory activity of PC may play an
important role in its OA disease-modifying activity.
We demonstrated that PC reduced the levels of
ADAMTS5 and MMP-13 proteins. It is worth noting
that the level of MMP-13 protein is much higher in the
middle zone than in the superficial and calcified zones
(Fig. 7). In human OA articular cartilage, calcium crys-
tals are detected in the superficial and calcified zones
[39–41]. If calcium crystals are also present in the super-
ficial or calcified zones of articular cartilage in the
guinea pigs and those crystals played a key role in the in-
duction of MMP-13 expression [42], high level of MMP-
13 protein should have been observed in the superficial
zone or calcified zone. Similarly, if the reduction in the
level of MMP-13 protein in PC treated guinea pigs was
due to the inhibition of PC on the interaction between
calcium crystals and chondrocytes [23], significant re-
duction in the level of MMP-13 protein should have
been observed in the superficial zone or calcified zone,
but not in the middle zone. However, these were not
what we observed, indicating that calcium-containing
crystals is unlikely a key inducer for the production of
MMP-13 in the articular cartilage and that PC exerts its
inhibitory effect on the production of MMP-13 through
a crystal-independent action.
Our findings do suggest that crystal-dependent action
of PC plays a role. For example, PC treatment resulted
in a 46 % reduction in the histological scores of cartilage
in meniscectomied right knee but a 54 % reduction in
non-operated left knee. One explanation for this differ-
ence (46 % reduction via 54 % reduction) is that patho-
logical meniscal calcification plays a role in the non-
operated left knee OA [7, 43]. It is likely that PC exerts
its disease-modifying effect on the posttraumatic OA in
the right knee through a crystal-independent action
whereas PC exerts its disease-modifying effect on the
primary OA in the left knee through both a crystal-
dependent action and a crystal-independent action. It is
conceivable that inhibition of cartilage degeneration
through a single action (inhibiting non-crystal-dependent
disease pathway) is less effective than through 2 actions
(inhibiting both crystal-dependent disease pathway and
non-crystal-dependent disease pathway).
PC-E was 46 % less powerful than PC in the inhibition
of cartilage degeneration in the non-operated left knee
but was 33 % less powerful than PC in the inhibition of
cartilage degeneration in the meniscectomied right knee.
Again, this difference (46 % reduction via 33 % reduc-
tion) can be explained similarly. The replacement of β-
carboxyl group with an ester group resulted in partial im-
pairment of both crystal-dependent action and crystal-
independent action of PC. It is conceivable that partial im-
pairment of both actions would result in a greater loss in
the disease-modifying effect on the primary OA in non-
operated left knee than on the posttraumatic OA in
meniscectomied right knee because crystal-dependent dis-
ease pathway was absent in the right knee.
Our study has limitations. One limitation is that the OA
in the meniscectomied right knee is not absolutely a non-
calcification-induced OA because crystals must be present
in the calcified zone. However, the increased severity of
Table 2 Differentially expressed genes in PC-treated and PC-E-treated cells compared with untreated cells (Continued)
IGFBP4 NM_001552 1.54 0.00 Insulin-like growth factor binding protein 4
PRKRA AA279462 1.53 0.00 Protein kinase, interferon-inducible RNA dependent
activator
TNFRSF11B NM_002546 1.50 −2.76 Tumor necrosis factor receptor superfamily, member
11b
BMPR1B AA935461 −2.12 0.00 Bone morphogenetic protein receptor, type IB
ANKH AF274753 −1.93 −1.71 Ankylosis, progressive homolog (mouse)
ACVR2A NM_001616 −1.89 0.00 Activin A receptor, type IIA
CYTL1 NM_018659 −1.83 0.00 Cytokine-like 1
TBX3 U69556 −1.71 1.77 T-box 3 (ulnar mammary syndrome)
SOX9 NM_000346 −1.71 0.00 SRY (sex determining region Y)-box 9
FOXC2 NM_005251 −1.68 0.00 Forkhead box C2 (MFH-1, mesenchyme forkhead 1)
KIAA1217 BC017424 −1.66 0.00 KIAA1217
MMP9 NM_004994 −1.61 0.00 Matrix metallopeptidase 9
TGFBR2 NM_003242 −1.51 −1.97 Transforming growth factor, beta receptor II
(70/80 kDa)
*Negative number indicates decreased expression (fold) in treated hTERT-OA 13A FLS compared with untreated cells
Positive number indicates elevated expression (fold) in treated hTERT-OA 13A FLS compared with the untreated cells
**Data was published previously [29]
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cartilage damage in the meniscectomied right knee com-
pared to the non-operated left knee indicate that the most
severe cartilage lesions in the right knee medial tibia plat-
eau, especially the cartilage lesions in the peripheral area,
were caused by meniscal injury and joint instability and
has little to do with pathological calcification. In addition,
a previous study found that PC had no significant effect
on crystal formation in cartilage [16]. Taken together, it in-
dicates that PC inhibits cartilage degeneration, at least in
part, through a crystal-independent action.
Conclusions
Posttraumatic OA in Hartley guinea pigs are character-
ized by breakdown of collagen fibers and proteoglycan
loss. PC is not only potentially a disease-modifying drug
for calcification-induced OA therapy but also poten-
tially a disease-modifying drug for posttraumatic OA
therapy. PC exerts its disease-modifying activity on OA
through two independent actions, a crystal-dependent
action and a crystal-independent action. The β-carboxyl
group plays little role in the proliferation-inhibitory ac-
tivity and the modulatory effect on the expressions of
genes classified in cell proliferation, but a major role in
the OA disease-modifying activity and the modulatory
effect on the expressions of genes classified in angiogen-
esis, inflammatory response, and skeletal system devel-
opment of PC. The β-carboxyl group is not a group that
should be used to link other active group(s) to create
new PC analogues as OA disease-modifying drugs.
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